Literature DB >> 33614303

Guillain-Barré Syndrome as a Complication of COVID-19.

Adeel S Zubair1, Aarij S Zubair2, Kunal Desai1, Ahmad Abulaban1, Bhaskar Roy1.   

Abstract

Coronavirus disease 2019 (COVID-19) is associated with multiple neurological complications including Guillain-Barre syndrome (GBS). While there are reports of COVID-19 -related GBS cases, much remain unknown. We report two cases of GBS-associated COVID-19, which started about eight weeks after the initial COVID-19 infection. Such a long duration between infection and symptom onset of GBS is unusual for post-infectious GBS. Moreover, severely ill patients with COVID-19 may have prolonged hospital stay leading to critical illness myoneuropathy. Diagnosing superimposed GBS can be challenging in such cases. Clinical suspicion, nerve conduction studies with electromyography, and cerebrospinal fluid analysis can help in making the correct diagnosis. Both presented cases responded to intravenous immunoglobulin therapy.
Copyright © 2021, Zubair et al.

Entities:  

Keywords:  coronavirus disease 19; covid-19; critical illness myopathy; critical illness polyneuropathy; guillain-barré syndrome; neurology; neuromuscular disorder

Year:  2021        PMID: 33614303      PMCID: PMC7883582          DOI: 10.7759/cureus.12695

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  2 in total

Review 1.  Guillain-Barré Syndrome in the COVID-19 Pandemic.

Authors:  Abdullah Ahmad Tawakul; Amal Waleed Al-Doboke; Shahad Ali Altayyar; Seham Abdulhafith Alsulami; Ahlam Musallam Alfahmi; Raghad Turki Nooh
Journal:  Neurol Int       Date:  2021-12-24

2.  Guillain Barré syndrome associated with COVID-19- lessons learned about its pathogenesis during the first year of the pandemic, a systematic review.

Authors:  Mayka Freire; Ariadna Andrade; Bernardo Sopeña; Maria Lopez-Rodriguez; Pablo Varela; Purificación Cacabelos; Helena Esteban; Arturo González-Quintela
Journal:  Autoimmun Rev       Date:  2021-06-10       Impact factor: 9.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.